Eliaz Therapeutics

Eliaz Therapeutics is developing a novel treatment using targeted therapeutic apheresis. Our mission is to change the course of life-threatening diseases to improve survival and prevent long-term disease and disability. Eliaz Therapeutics is developing a novel medical device to selectively remove galectin-3 from the bloodstream. Galectin-3 (Gal-3) is an important mediator and known key driver of organ inflammation and fibrosis in numerous acute and chronic progressive conditions. In critically ill patients, the development of AKI and sepsis is associated with increased plasma Gal-3 levels. When Gal-3 is blocked in animal models, AKI rates significantly decrease and survival increases.